Nasjonal Beredskapsplan Pandemisk Influensa

Objectives

Norway’s National Pandemic Influenza Preparedness Plan provides a cross-government framework to prevent and limit transmission, illness and death, deliver treatment and care, sustain public trust, and maintain essential societal functions during an influenza pandemic.[1][2]It is primarily directed at health authorities and healthcare providers but requires preparedness across ministries, public services, businesses and other societal sectors.[3][2]

• Prepare for a moderate-to-severe pandemic, using a planning assumption that 50% of the population may be infected and half of those infected may become ill, while retaining flexibility for less severe or more severe events.[4]
• Organise action around planning and coordination, surveillance and assessment, prevention and mitigation, response, and communication, aligned broadly with World Health Organization pandemic phases.[5][6]
• Prioritise preventing deaths, then illness, and maintaining vital societal functions through vaccination, antivirals, hygiene and other infection-control measures.[4][7]
• Secure pandemic-vaccine access for the whole population, recognising vaccination as the most effective intervention while acknowledging that virus-specific supply may be delayed and initially limited.[8][9]
• Apply ethical prioritisation based on equal human worth, severity and expected benefit, rather than age alone, when vaccines, antivirals or health-service capacity are scarce.[10][11]
• Adapt national measures to continuously updated assessments of transmission, clinical severity, population vulnerability, healthcare capacity and local circumstances rather than treating global pandemic phases as rigid operational triggers.[12][13][14]
• Plan for substantial health-service demand in the recommended scenario of a 25% clinical attack rate, including approximately 160,000 to 280,000 additional healthcare contacts, 14,000 to 16,500 additional hospital admissions, and 1,400 to 2,800 intensive-care patients.[15]

Implementation

Implementation combines a national framework, a thematic and chronological phase-based action plan, and technical evidence, which actors are expected to consider together and incorporate into their own preparedness arrangements.[1][2]Delivery relies on existing statutory responsibilities, crisis-management structures, health services, surveillance systems, medicine supply chains and international cooperation.[7][16]

• Maintain ministerial responsibility under the principle that the body responsible in normal circumstances also leads within its remit during a crisis, supported by strategic coordination through the Crisis Council and the Crisis Support Unit.[16][17][18]
• Assign the Ministry of Health and Care Services overall responsibility for health-sector security and preparedness, cross-sector coordination, national pandemic-phase transitions and final designation of a disease as generally dangerous.[19][20]
• Use the Norwegian Directorate of Health to manage outbreak-control situations, coordinate services and, where legally necessary, direct authorities or impose national or local restrictions.[20]
• Use the Norwegian Institute of Public Health for national infection-control advice, field epidemiology, outbreak investigation, vaccine preparedness, reference laboratory functions, influenza surveillance and national contact-point duties with the World Health Organization and European partners.[21][22]
• Require municipalities and specialist health services to develop, exercise, review and update their own pandemic, infection-control and emergency plans, covering leadership, communications, staffing, patient pathways, isolation, treatment, medicines, equipment, vaccination and continuity of care.[4][23][24]
• Maintain surveillance through clinical, virological, laboratory, vaccination and adverse-event systems, including weekly reporting, strengthened reporting during a pandemic, rapid case notification and repeated risk assessments.[25][26][27]
• Operate the Pandemic Committee as an advisory and consultation body led by the Directorate of Health, with secretariat support from the Norwegian Institute of Public Health; review whether the national plan requires revision annually.[28][29]
• Manage national stocks of antivirals and medical supplies, distribute antivirals through wholesalers and pharmacies, and prepare agreements on distribution, dispensing, traceability, reimbursement and possible patient charges.[21][30][31]
• Procure and centrally distribute pandemic vaccines through the Norwegian Institute of Public Health, while municipalities, health trusts and the Armed Forces organise vaccination for their relevant populations and staff.[32][33]
• Register pandemic vaccinations in the National Immunisation Register, SYSVAK, and monitor serious suspected adverse events through reporting to the Norwegian Institute of Public Health and medicines-safety systems.[34][35]
• Use coordinated, evidence-based communication through national and local authorities, websites, telephone services, media and direct networks, with information adapted to the public, health professionals and groups unable to use Norwegian.[36][37][38]
• Co-operate through the World Health Organization, European Union, European Economic Area and Nordic mechanisms on surveillance, warning, information-sharing, medicines, vaccines, mutual assistance and response coordination.[39][40][41]
• Exercise plans, assess preparedness gaps, evaluate incidents and communications, and incorporate lessons into systematic plan improvement; the source does not specify a consolidated quantitative performance-indicator framework or a national pandemic-preparedness budget.[16][29][42]

Monitoring & Evaluation

The monitoring and evaluation framework combines surveillance, risk assessment, notification, plan review, exercises, vaccination registration, adverse-event monitoring and statutory supervision. It prioritises timely situational awareness to guide proportionate decisions throughout pandemic phases, while leaving most quantitative performance targets and evaluation methodologies unspecified.[5][29][43][34]

• Maintain integrated clinical, virological and laboratory surveillance through general practices, out-of-hours services, medical microbiology laboratories and the Norwegian Institute of Public Health (FHI). Weekly clinical reporting covers influenza-like illness, while the Disease Pulse system collects continuous diagnosis data from general practitioners.[25]
• Monitor influenza-related hospital admissions, deaths, vaccination coverage, vaccine adverse reactions, antiviral resistance, healthcare capacity and the effects of control measures.[44][45][26]
• Report surveillance data nationally and internationally each week, publish weekly reports, and expand reporting frequency or participating units when a pandemic requires faster or more detailed information.[26]
• Conduct repeated local, national and international risk assessments of transmissibility, clinical severity, population vulnerability, healthcare demand and available response capacity.[46][14]
• Assess severity using attack rates, hospital and intensive-care requirements, deaths, affected age groups, pressure on primary and specialist services, ventilators, extracorporeal membrane oxygenation equipment, laboratory capacity and surveillance systems.[14]
• Notify serious national and international public-health events through statutory channels. FHI must assess events in Norway within 48 hours and notify the World Health Organization within a further 24 hours where an event may constitute a public-health emergency of international concern.[47][48]
• Maintain national contact-point functions under the International Health Regulations, including continuous availability for World Health Organization communication and onward notification to the Ministry of Health and Care Services, the Norwegian Directorate of Health and other relevant authorities.[22]
• Register all pandemic vaccinations in the National Immunisation Register, SYSVAK, using electronic systems to provide continuous information on individual vaccination status, population coverage, vaccine availability and effectiveness.[34]
• Require health professionals to report suspected serious vaccine adverse events promptly to FHI, which processes reports for the Norwegian Medicines Agency and shares relevant information with European, World Health Organization and manufacturers’ databases.[35]
• Review the pandemic plan annually through the Pandemic Committee, report the review to the Ministry of Health and Care Services, and assess whether revisions are needed.[28][29]
• Exercise plans, alert systems, reporting lines and communication channels at all administrative levels; regularly update preparedness plans and incorporate lessons from exercises and incidents through systematic improvement.[2][16]
• Use statutory supervision by the Norwegian Board of Health Supervision to assess whether municipal, county and state bodies comply with legal requirements and maintain required preparedness plans.[22]
• Evaluate the effectiveness, feasibility and impact of infection-control measures, treatment, countermeasures, vaccine coverage and safety after pandemic waves and during post-pandemic recovery.[49][50]
• Assess communication through public knowledge, attitudes, trust, risk understanding, information needs and feedback collected through telephone, email and social-media channels.[36][37][51]

No consolidated indicator framework, independent evaluation methodology, universal reporting timetable, audit schedule or quantified accountability targets is specified beyond the surveillance, notification, registration, review, exercise and statutory-supervision arrangements described.[5][52][25]

Costing & Financing

The plan identifies substantial preparedness resources and supply-chain arrangements for medicines, vaccines, diagnostics, protective equipment, staffing and communication, but does not provide a national budget, costed implementation plan, funding-gap estimate or quantified economic assumptions.[29][53][23]

• Maintain national contingency stocks of antivirals, medicines, medical supplies and vaccines, while requiring hospitals and health enterprises to secure antibiotics for secondary infections and regularly update requirements for equipment, consumables, syringes and needles.[21][53]
• Assess and mobilise additional human and material resources, including healthcare personnel, hospital capacity, medical equipment, infrastructure, vaccines and other supplies as the pandemic develops.[54][55][45]
• Use agreements with pharmaceutical wholesalers, pharmacies and software providers to support antiviral release, distribution, traceability, reimbursement and patient-payment arrangements.[30]
• Compensate wholesalers and pharmacies for antiviral distribution and dispensing activities under arrangements agreed in advance.[30][31]
• Allow the Ministry to decide that medicines or vaccines are supplied free to people at risk of infection or already infected; alternatively, permit an as-yet-undetermined patient co-payment.[30][31][33][34]
• Agree a fixed tariff for vaccination services before mass vaccination, while allowing private and municipal vaccinators to charge for each vaccination and leaving responsibility for that charge to either the patient or public sector.[34]
• Maintain an agreement enabling pandemic-vaccine orders for the whole population, although initial supply may only arrive four to six months after production starts and may be delivered in smaller consignments over time.[9]
• Plan resource allocation for surveillance, laboratory diagnostics, field epidemiology, vaccine administration, mass vaccination, additional staff, volunteers and continuity of essential services.[29][43][56]
• Consider economic compensation for culling animals where this would improve compliance with measures to contain animal outbreaks.[54]
• Recognise that some interventions, including hygiene information, are simple and inexpensive, whereas population-wide restrictions, border closures, quarantine and mass traveller screening may impose substantial resource demands or very large costs with limited benefit.[57][58]
• Recognise that manufacturers receiving influenza viruses through the Pandemic Influenza Preparedness Framework are required to contribute financially to preparedness and make vaccines and diagnostics available to the World Health Organization during a pandemic, without a stated monetary amount.[41]
• Anticipate possible substantial price reductions in antivirals following expected expiry of the Tamiflu patent in 2016, although no price estimate is provided.[59]

Funding sources, budget allocations, procurement prices, stockpile values, service tariffs, patient charges, financing gaps and economic modelling assumptions are not quantified in the supplied material.[59][9][34]